Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
March 14 2018 - 8:00AM
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage
company developing and commercializing novel antibiotics to treat
serious bacterial infections, announced today that Dan Wechsler,
President and CEO of Melinta, will be presenting at Needham &
Company’s 17th Annual Healthcare Conference in New York, NY. Mr.
Wechsler’s presentation will take place on Tuesday, March 27, 2018
at 12:45pm Eastern Time. A live and archived webcast of the
presentation will be accessible from the Melinta Events &
Presentations section of the Investors webpage.
Needham & Company’s Annual Healthcare Conference is host to
over 130 public and private companies across the life sciences
sectors. It is taking place March 27-28, 2018 at the Westin Grand
Central Hotel in New York, NY.
About Melinta Therapeutics Melinta
Therapeutics, Inc. is the largest pure-play antibiotics company,
dedicated to saving lives threatened by the global public health
crisis of bacterial infections through the development and
commercialization of novel antibiotics that provide new and better
therapeutic solutions. Its four marketed products include Baxdela™
(delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv®
(oritavancin), and Minocin® (minocycline) for Injection. It also
has an extensive pipeline of preclinical and clinical-stage
products representing many important classes of antibiotics, each
targeted at a different segment of the anti-infective market.
Together, this portfolio provides Melinta with the unique ability
to provide providers and patients with a range of solutions that
can meet the tremendous need for novel antibiotics treating serious
infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:Amra Maynard(917)
302-2702Amra.maynard@inventivhealth.com
Investor Inquiries:Lisa DeFrancesco(847)
681-3217ldefrancesco@melinta.com
Raj Mistry(312) 801-2051rmistry@melinta.com
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Apr 2023 to Apr 2024